Pharma company Pfizer posted a -1.69% performance today, while the S&P 500 returned 0.62%.
20 analysts are following Pfizer and have set target prices ranging from $40.0 to $75.0 per share. On average, they have given the company a rating of buy. At today's prices, PFE is trading -21.85% away from its average analyst target price of $52.52 per share.
Over the last year, PFE shares have gone down by -9.53%, which represents a difference of -0.3% when compared to the S&P 500. The stock's 52 week high is $54.46 per share and its 52 week low is $40.72. With average free cash flows of $18,227,400,000 that have been growing at an average rate of 26.78% over the last four years, Pfizer declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations (k) | Capital Expenditures (k) | Free Cash Flow (k) | YoY Growth |
|---|---|---|---|---|
| 2022-12-31 | $29,267,000 | $3,236,000 | $26,031,000 | -12.85% |
| 2021-12-31 | $32,580,000 | $2,711,000 | $29,869,000 | 157.23% |
| 2020-12-31 | $14,403,000 | $2,791,000 | $11,612,000 | 16.19% |
| 2019-12-31 | $12,588,000 | $2,594,000 | $9,994,000 | -26.68% |
| 2018-12-31 | $15,827,000 | $2,196,000 | $13,631,000 | n/a |
